Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis

Clinical Infectious Diseases

Volumn 62, Issue 9, 2016, Pages 1100-1110

  Fulton, T Roice ^a,b   Phadke, Varun K ^c   Orenstein, Walter A ^a,c   Hinman, Alan R ^d   Johnson, Wayne D ^b   Omer, Saad B ^a,b,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Task Force for Global Health   (United States)

Author keywords

acellular; meta analysis; Pertussis; vaccine efficacy effectiveness; whole cell

Indexed keywords

PERTUSSIS VACCINE;

ARTICLE; DRUG EFFICACY; DRUG FORMULATION; EFFECT SIZE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PERTUSSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; CHILD; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; TREATMENT OUTCOME; WHOOPING COUGH;

CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; PERTUSSIS VACCINE; TREATMENT OUTCOME; WHOOPING COUGH;

EID: 84966691968     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw051     Document Type: Article

References (39)

1. Adams DA, Jajosky RA, Ajani U, et al. Summary of notifiable diseases-United States, 2012. MMWR Morb Mortal Wkly Rep 2014; 61:1-121.
2. NNDSS Annual Report Writing Group. Australia's notifiable disease status, 2012: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell Q Rep 2015; 39:E46-136.
3. Tan TQ, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 24(5 suppl):S10-8.
4. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24(5 suppl):S58-61.
5. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012-9.
6. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126-32.
7. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52.
8. Sin MA, Zenke R, Ronckendorf R, Littmann M, Jorgensen P, Hellenbrand W. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. Pediatr Infect Dis J 2009; 28:242-4.
9. Lai FY, Thoon KC, Ang LW, et al. Comparative seroepidemiology of pertussis, diphtheria and poliovirus antibodies in Singapore: waning pertussis immunity in a highly immunized population and the need for adolescent booster doses. Vaccine 2012; 30:3566-71.
10. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; 56:1248-54.
11. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454-6.
12. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46:1-25.
13. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96(3 II suppl):557-66.
14. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334:341-8.
15. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55.
16. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350:1569-77.
17. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussistoxoid vaccine. N Engl J Med 1995; 333:1045-50.
18. Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997; 16:1038-44.
19. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101:1-11.
20. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15:1606-12.
21. Schmitt HJ, Von Konig CHW, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41.
22. Cherry JD. Why do pertussis vaccines fail? Pediatrics 2012; 129:968-70.
23. McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015; 135:331-43.
24. Boschi-Pinto C, Young M, Black RE. The Child Health Epidemiology Reference Group reviews of the effectiveness of interventions to reduce maternal, neonatal and child mortality. Int J Epidemiol 2010; 39(suppl 1):i3-6.
25. Walker N, Fischer-Walker C, Bryce J, Bahl R, Cousens S. Standards for CHERG reviews of intervention effects on child survival. Int J Epidemiol 2010; 39(suppl 1):i21-31.
26. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985; 63:1055-68.
27. World Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Available at: http://apps.who.int/iris/bitstream/10665/68334/1/WHO-V-B-03.01-eng.pdf. Accessed 18 December 2015.
28. World Health Organization, Division of Communicable Diseases. WHO meeting on case definition of pertussis, Geneva, 10-11 January 1991. Geneva, Switzerland: WHO, 1991.
29. Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th ed. Philadelphia, PA: Elsevier Saunders, 2013.
30. Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Atlanta, GA, 2015.
31. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011; 342:d549.
32. Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005; 116:e285-94.
33. Rendi-Wagner P, Kundi M, Mikolasek A, Vecsei A, Fruhwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 2006; 24:5960-5.
34. Juretzko P, Von Kries R, Hermann M, et al. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002; 35:162-7.
35. Preziosi MP, Halloran ME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis 2003; 37:772-9.
36. Torvaldsen S, Simpson JM, McIntyre PB. Effectiveness of pertussis vaccination in New South Wales, Australia, 1996-1998. Eur J Epidemiol 2003; 18:63-9.
37. Zielinski A, Rosinska M, Czarkowski M, Rudowska J. The effectiveness of vaccination with whole-cell pertussis vaccine by age group in Poland 1996-2001. Scand J Infect Dis 2004; 36:114-8.
38. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2014; 9:CD001478.
39. Fine PE, Mulholland K. Community immunity. In: Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th ed. Elsevier Saunders, 2013.